2025 年 8 月 27 日 招银国际环球市场 | 市场策略 | 招财日报 每日投资策略 公司点评 公司点评 时代天使（6699 HK，买入，目标价：86.47 港元）- 海外业务驱动快速增长 时代天使公布强劲的 2025 年上半年业绩，收入同比增长 33%至 1.6 亿美元， 主要受海外业务快速扩张驱动。隐形矫治总病例数达 225,800 例，同比增加 48%，达到此前我们全年预测的 51.7%，高于历史平均约 41%。归母净利率 招银国际研究部 邮件：research@cmbi.com.hk | 环球主要股市上日表现 | | | | | --- | --- | --- | --- | | | 收市价 | | 升跌（%） | | | | 单日 | 年内 | | 恒生指数 | 25,525 | -1.18 | 27.24 | | 恒生国企 | 9,149 | -1.07 | 25.50 | | 恒生科技 | 5,782 | -0.74 | 29.41 | | 上证综指 | 3,868 | -0.39 | 15.41 | | 深证综指 | 2,441 | 0.18 | 24.69 | | 深圳创业板 | 2, ...

Macro Strategy - The report suggests that the overlap of population peak and consumption peak from 2025 to 2035 may lead to more optimistic growth in total consumption compared to 2020-2025, as the proportion of the population aged 40-49 is expected to increase from 13.8% to 15.9% [1] Fixed Income - The report indicates that the bond market is experiencing a slight upward trend in yields due to the recent reserve requirement ratio cut, with expectations for the DR007 to stabilize around 1.4%-1.5% [3][4] - The issuance of secondary capital bonds totaled 400 billion yuan, with a trading volume of approximately 242.4 billion yuan, reflecting an increase of 53.8 billion yuan from the previous week [4] - Green bond issuance reached 10 bonds with a total scale of approximately 10.3 billion yuan, an increase of 2.5 billion yuan from the previous week [5] Real Estate - New housing transaction area increased month-on-month, while second-hand housing transactions also saw a rise, indicating a potential recovery in the real estate market [6] - The report recommends several companies in real estate development, property management, and real estate brokerage, including China Resources Land, Poly Developments, and Beike [6] Engineering Machinery - The report highlights a year-on-year increase of 18% in excavator sales for April, indicating a positive outlook for the engineering machinery industry [7] Gas Industry - The report anticipates a relaxed supply situation for gas companies, with a focus on cost optimization and price mechanism adjustments, recommending companies like Xin'ao Energy and China Gas [9] Petrochemical Industry - The report notes a significant increase in polyester prices, with POY, FDY, and DTY prices rising by 5.5%, 5.9%, and 3.9% respectively, indicating strong demand in the petrochemical sector [10] Retail Industry - The report emphasizes the strong performance of domestic brands during the 618 shopping festival, recommending companies like Ruya Chen and Juzhi Biological [11] Construction Materials - The report indicates a stable economic outlook with improved supply dynamics in the construction materials sector, recommending companies like China Communications Construction and China Railway Construction [12][18] Automotive Industry - The report maintains a positive outlook for the automotive sector, highlighting a 6.5% month-on-month increase in passenger car sales, with a focus on AI and robotics as key growth drivers [19] Pharmaceutical Industry - The report identifies a fast track for the development of three-antibody drugs, recommending companies like Zai Lab and 3SBio for investment [21][22] Electronic Industry - The report discusses the growing demand for AI infrastructure, particularly in the Middle East, and suggests focusing on domestic hardware suppliers for AI applications [23] Non-Banking Financial Industry - The report highlights the low average valuation in the non-banking financial sector, recommending companies like New China Life Insurance and CITIC Securities for investment [25]

Macro Commentary - The US economy shows signs of slowing down, with significant declines in retail and manufacturing output due to tariff impacts, particularly affecting durable goods like automobiles and electronics [2] - Despite the slowdown, unemployment claims remain stable, indicating that the service sector is less affected, and employment in this sector remains robust [2] - Inflation is expected to rebound temporarily from May to August, with the Federal Reserve likely to maintain interest rates until September, when a potential rate cut may occur [2] Industry Commentary - The Chinese pharmaceutical sector is experiencing a strong trend in innovative drug exports, with several significant business development transactions occurring despite recent tariff tensions [5][6] - The MSCI China Healthcare Index has risen by 14.9% since early 2025, although it has underperformed compared to the broader MSCI China Index [5] - The US innovative drug prices are unlikely to decrease in the short term due to recent executive orders, but long-term pressures on healthcare spending are anticipated [7] Company Initiation - The report covers Angelalign Technology (6699 HK), a leading provider of invisible orthodontic solutions in China, which has maintained a market share of 42% in the domestic market [9][10] - The company is expected to achieve a revenue compound annual growth rate (CAGR) of 23.8% from 2019 to 2024, with a projected CAGR of 18.0% from 2024 to 2027 [9] - Angelalign is expanding internationally, with a goal to cover over 50 countries and achieve significant revenue growth from overseas markets, which is expected to account for 30% of total revenue by 2024 [11][12]